Drugs Made In America Acquisition Corp. (DMAA)
NASDAQ: DMAA · Real-Time Price · USD
10.56
-0.01 (-0.09%)
At close: Apr 28, 2026, 4:00 PM EDT
10.57
+0.01 (0.09%)
After-hours: Apr 28, 2026, 4:00 PM EDT
Company Description
Drugs Made In America Acquisition Corp. does not have significant operations.
It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses.
Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in Fort Lauderdale, Florida.
Drugs Made In America Acquisition Corp.
| Country | United States |
| Founded | 2024 |
| IPO Date | Jan 28, 2025 |
| Industry | Shell Companies |
| Sector | Financials |
| CEO | Roger Bendelac |
Contact Details
Address: 1 East Broward Boulevard, Suite 700 Fort Lauderdale, Florida 33301 United States | |
| Phone | 954 870 3099 |
| Website | dmaacorp.com |
Stock Details
| Ticker Symbol | DMAA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0002028614 |
| ISIN Number | KYG2847J1040 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Roger Bendelac | Chief Executive Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2026 | DEFR14A | Filing |
| Apr 15, 2026 | 10-K | Annual Report |
| Apr 14, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 8, 2026 | 8-K | Current Report |
| Apr 1, 2026 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 27, 2026 | PRE 14A | Other preliminary proxy statements |
| Mar 27, 2026 | 8-K | Current Report |
| Mar 6, 2026 | 8-K | Current Report |
| Mar 6, 2026 | 8-K | Current Report |
| Nov 18, 2025 | 10-Q | Quarterly Report |